Adverse effects of antimalarial prophylactic drugs: an important consideration in the risk-benefit equation.
Davis
T M
TM
Department of Medicine, University of Western Australia. tdavis@cyllene.uwa.edu.au
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000962:Antimalarials / Q000009:adverse effects* / Q000627:therapeutic use; D053626:Atovaquone; D017963:Azithromycin / Q000009:adverse effects / Q000627:therapeutic use; D002738:Chloroquine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000517:prevention & control; D015767:Mefloquine / Q000009:adverse effects / Q000627:therapeutic use; D009285:Naphthoquinones / Q000009:adverse effects / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects; D010966:Plasmodium vivax / Q000187:drug effects; D011319:Primaquine / Q000009:adverse effects / Q000627:therapeutic use; D002727:Proguanil / Q000009:adverse effects / Q000627:therapeutic use; D011739:Pyrimethamine / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D009285:Naphthoquinones; D017963:Azithromycin; D002738:Chloroquine; D011319:Primaquine; D002727:Proguanil; D015767:Mefloquine; D053626:Atovaquone; D011739:Pyrimethamine